Acurx Pharmaceuticals, Inc.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a publicly held, clinical-stage biopharmaceutical company focused on developing a new class of antibiotics for infections caused by priority pathogens identified by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.

Products & Services

Ibezapolstat:A product in the pipeline, likely an antibiotic for specific infections (details not specified in content).

GPSS(r):A product in the pipeline, specifics not provided in the content.

Specialties

Development of new antibiotics Treatment of infections caused by priority pathogens

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 375000 MR: - FA: approximately $375,000 USD FAN: 375000	D: 2025-11-18 FD: 2025-11-18	1 investors
2	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2670000 MR: - FA: approximately $2.67 million FAN: 2670000	D: 2025-06-17 FD: 2025-06-17	1 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1100000 MR: - FA: approximately $1.1 million FAN: 1100000	D: 2025-03-10 FD: 2025-03-10	-
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1100000 MR: - FA: $1.1 million FAN: 1100000	D: 2025-03-07 FD: 2025-03-07	-
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2500000 MR: - FA: $2.5 million FAN: 2500000	D: 2025-01-07 FD: 2025-01-07	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2500000 MR: - FA: $2.5 Million FAN: 2500000	D: 2025-01-06 FD: 2025-01-06	1 investors
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: 4.0 million FAN: 4000000	D: 2023-05-16 FD: 2023-05-16	1 investors

Grant Latest

2025-11-18

$375K

1 investor (Pro only)

Warrant Exercise 2025-06-17

$2.7M

Registered Direct Offering 2025-03-10

$1.1M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jack H. Dean

Ph.D., Former Director, Worldwide Pre-Clinical Research at Sanofi; Research Professor at Univ of Arizona

R

Robert J. DeLuccia

Executive Chairman

J

James Donohue

Director

T

Thomas Harrison

Director

D

David P. Luci

President and Chief Executive Officer

C

Carl Sailer

Director

View 16 more team members with Pro

Unlock Full Team Directory

Recent News